{
  "@context": {
    "schema": "https://schema.org/",
    "fabio": "http://purl.org/spar/fabio/",
    "cito": "http://purl.org/spar/cito/",
    "dcterms": "http://purl.org/dc/terms/",
    "foaf": "http://xmlns.com/foaf/0.1/",
    "bibo": "http://purl.org/ontology/bibo/",
    "go": "http://purl.obolibrary.org/obo/GO_",
    "doid": "http://purl.org/obo/DOID_",
    "chebi": "http://purl.org/obo/CHEBI_",
    "atc": "http://purl.org/obo/ATC_",
    "pw": "http://purl.org/obo/PW_",
    "eco": "http://purl.org/obo/ECO_",
    "mondo": "http://purl.org/obo/MONDO_",
    "comptox": "https://comptox.epa.gov/",
    "mesh": "http://id.nlm.nih.gov/mesh/"
  },
  "@id": "https://doi.org/10.1234/62408",
  "@type": "bibo:AcademicArticle",
  "dcterms:title": "Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta",
  "dcterms:creator": [
    {
      "@id": "https://orcid.org/0000-0002-1234-5678",
      "@type": "foaf:Person",
      "foaf:name": "Alexandra J Weigand"
    },
    {
      "@id": "https://orcid.org/0000-0001-2345-6789",
      "@type": "foaf:Person",
      "foaf:name": "Lauren Edwards"
    },
    {
      "@id": "https://orcid.org/0000-0003-2345-6789",
      "@type": "foaf:Person",
      "foaf:name": "Kelsey R Thomas"
    },
    {
      "@id": "https://orcid.org/0000-0004-2345-6789",
      "@type": "foaf:Person",
      "foaf:name": "Katherine J Bangen"
    },
    {
      "@id": "https://orcid.org/0000-0005-2345-6789",
      "@type": "foaf:Person",
      "foaf:name": "Mark W Bondi"
    }
  ],
  "dcterms:abstract": "Recently proposed biomarker-only diagnostic frameworks propose that amyloid-beta is necessary for placement on the Alzheimer’s disease continuum, whereas tau in the absence of amyloid-beta is considered to be a non-Alzheimer’s disease pathologic change. Similarly, the pathologic designation of tau in the absence of amyloid-beta is characterized as primary age-related tauopathy and separable from Alzheimer’s disease.",
  "schema:datePublished": "2022-10-24",
  "schema:keywords": [
    "Alzheimer’s disease",
    "primary age-related tauopathy",
    "biomarkers",
    "amyloid-beta",
    "tau"
  ],
  "fabio:hasPublicationVenue": {
    "@id": "https://journals.somejournal.com/article/10.1234/62408",
    "@type": "fabio:Journal",
    "schema:name": "Brain Communications"
  },
  "fabio:hasPart": [
    {
      "@id": "section1",
      "@type": "fabio:Section",
      "dcterms:title": "Introduction",
      "fabio:hasContent": "Alzheimer’s disease has historically been characterized by the presence of two pathologic proteins, amyloid-beta and phosphorylated tau."
    },
    {
      "@id": "section2",
      "@type": "fabio:Section",
      "dcterms:title": "Methods",
      "fabio:hasContent": "The study included 703 participants without dementia from ADNI who had concurrent Aβ PET, tau PET and demographic data."
    }
  ],
  "cito:cites": [
    {
      "@id": "https://doi.org/10.1038/s41586-020-05022-5",
      "@type": "bibo:AcademicArticle",
      "dcterms:title": "Understanding Alzheimer's disease pathways",
      "bibo:doi": "10.1038/s41586-020-05022-5"
    },
    {
      "@id": "https://doi.org/10.1016/j.neurobiolaging.2019.08.006",
      "@type": "bibo:AcademicArticle",
      "dcterms:title": "Tau pathology and cognition",
      "bibo:doi": "10.1016/j.neurobiolaging.2019.08.006"
    }
  ],
  "cito:discusses": [
    {
      "@id": "http://purl.obolibrary.org/obo/GO_0008150",
      "schema:name": "biological_process"
    },
    {
      "@id": "http://purl.org/obo/DOID_14330",
      "schema:name": "lung cancer"
    }
  ]
}